What question did this study set out to answer?

To determine whether SLFN11 expression predicts sensitivity to PARP inhibitor monotherapy and to evaluate potential synergy when combined with temozolomide in small cell lung cancer.

July 20, 2016Clinical Cancer Research

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

To determine whether SLFN11 expression predicts sensitivity to PARP inhibitor monotherapy and to evaluate potential synergy when combined with temozolomide in small cell lung cancer.
Assessed PARP inhibitor response in preclinical small cell lung cancer models in correlation with SLFN11 biomarker expression.
Evaluated the antitumor efficacy of combining PARP inhibition with the DNA-damaging agent temozolomide.
SLFN11 expression functions as a predictive biomarker of tumor response and sensitivity to single-agent PARP inhibition in small cell lung cancer.
Combinatorial therapy pairing PARP inhibitors with temozolomide demonstrates strong synergistic activity over monotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Translational study demonstrates SLFN11-dependent PARP inhibitor sensitivity and synergy with temozolomide in small cell lung cancer, indicating promising therapeutic combination strategies.

Cite This Study

Lok et al. (2016) studied this question.

synapsesocial.com/papers/69d6c49aa0177bf533ed8eba https://doi.org/10.1158/1078-0432.ccr-16-1040

View Full Paper

Ask AI

Bookmark

Implication

Translational study demonstrates SLFN11-dependent PARP inhibitor sensitivity and synergy with temozolomide in small cell lung cancer, indicating promising therapeutic combination strategies.

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

Key Points

Discussion

Implication

Cite This Study

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider